Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04132817
What this trial is testing

Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 12
Large-scale testing (Phase 3)Study completedNCT06009627
What this trial is testing

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 119
Testing effectiveness (Phase 2)Study completedNCT00691379
What this trial is testing

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 46
Testing effectiveness (Phase 2)Ended earlyNCT05180006
What this trial is testing

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 33
Testing effectiveness (Phase 2)Ended earlyNCT02983604
What this trial is testing

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Who this might be right for
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Gilead Sciences 14
Large-scale testing (Phase 3)Active Not RecruitingNCT02810743
What this trial is testing

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 174
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255
What this trial is testing

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Who this might be right for
Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more
Dana-Farber Cancer Institute 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT05708235
What this trial is testing

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Who this might be right for
Breast Cancer
MedSIR 976
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05501886
What this trial is testing

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Who this might be right for
Breast Cancer
Celcuity Inc 701
Large-scale testing (Phase 3)Looking for participantsNCT06954961
What this trial is testing

Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 640
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Testing effectiveness (Phase 2)Active Not RecruitingNCT03742102
What this trial is testing

Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
AstraZeneca 243
Testing effectiveness (Phase 2)Active Not RecruitingNCT00616967
What this trial is testing

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 68
Testing effectiveness (Phase 2)Looking for participantsNCT07311577
What this trial is testing

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

Who this might be right for
Ovarian Cancer MetastaticOvarian Cancer Metastatic Recurrent
Jiangsu Cancer Institute & Hospital 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845
What this trial is testing

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Nancy Chan, MD 47
Very early researchEnded earlyNCT03361800
What this trial is testing

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Who this might be right for
Breast CancerInvasive Breast CancerER-Negative PR-Negative HER2-Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center 5
Not applicableStudy completedNCT06572800
What this trial is testing

Tka Assay for CDK4/6i

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma
Yale University 34
Testing effectiveness (Phase 2)UnknownNCT03907098
What this trial is testing

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Large-scale testing (Phase 3)Looking for participantsNCT07085767
What this trial is testing

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 1,000
Next Page